Clinical Trials · NCT01224717
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novartis
- Enrollment
- 104
- Start date
- Sep 2010
- Locations
- 4 sites, Denmark, Germany
- Primary endpoint
- Measure: Effects of treatment on bone biomarkers. Measure levels of PINP, CTX-1, and serum calcium levels, serum phosphate, P1CP, bone-specific alkaline phosphatase, osteocalcin.